Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute M Moll

Showing results (21-30 of 94) with videos related to

Pageof 10
Sort By:
Cell Cycle (Georgetown, Tex.)|July 17, 2007
The role of ubiquitination in the direct mitochondrial death program of p53Natasha D Marchenko, Ute M Moll
Cancers|June 8, 2018
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic TargetRamona Schulz-Heddergott, Ute M Moll
Methods in Molecular Biology (Clifton, N.J.)|November 15, 2012
Generation of p53-deficient induced pluripotent stem cells from mouse embryo fibroblastsEvguenia M Alexandrova, Ute M Moll
Molecular and Cellular Biology|August 5, 2003
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivoOleksi Petrenko, Alexander Zaika, Ute M Moll
Methods in Molecular Biology (Clifton, N.J.)|June 26, 2003
Mutational analysis of p53 in human tumors: direct DNA sequencing and SSCPSusan Erster, Neda Slade, Ute M Moll
Nucleic Acids Research|March 3, 2004
Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNAPetr Pancoska, Zdenek Moravek, Ute M Moll
Nucleic Acids Research|August 31, 2004
Rational design of DNA sequences for nanotechnology, microarrays and molecular computers using Eulerian graphsPetr Pancoska, Zdenek Moravek, Ute M Moll
Cell Cycle (Georgetown, Tex.)|March 2, 2010
p63 and canonical Wnt signalingFlaminia Talos, Ramona Schulz, Ute M Moll
Oncoimmunology|December 18, 2012
HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidatesRamona Schulz, Matthias Dobbelstein, Ute M Moll
Journal of Molecular Cell Biology|December 9, 2016
Mdm2 as a chromatin modifierMagdalena Wienken, Ute M Moll, Matthias Dobbelstein
Pageof 10

Showing results (21-30 of 94) with videos related to

Sort By:
Pageof 10
Cell Cycle (Georgetown, Tex.)|July 17, 2007
The role of ubiquitination in the direct mitochondrial death program of p53Natasha D Marchenko, Ute M Moll
Cancers|June 8, 2018
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic TargetRamona Schulz-Heddergott, Ute M Moll
Methods in Molecular Biology (Clifton, N.J.)|November 15, 2012
Generation of p53-deficient induced pluripotent stem cells from mouse embryo fibroblastsEvguenia M Alexandrova, Ute M Moll
Molecular and Cellular Biology|August 5, 2003
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivoOleksi Petrenko, Alexander Zaika, Ute M Moll
Methods in Molecular Biology (Clifton, N.J.)|June 26, 2003
Mutational analysis of p53 in human tumors: direct DNA sequencing and SSCPSusan Erster, Neda Slade, Ute M Moll
Nucleic Acids Research|March 3, 2004
Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNAPetr Pancoska, Zdenek Moravek, Ute M Moll
Nucleic Acids Research|August 31, 2004
Rational design of DNA sequences for nanotechnology, microarrays and molecular computers using Eulerian graphsPetr Pancoska, Zdenek Moravek, Ute M Moll
Cell Cycle (Georgetown, Tex.)|March 2, 2010
p63 and canonical Wnt signalingFlaminia Talos, Ramona Schulz, Ute M Moll
Oncoimmunology|December 18, 2012
HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidatesRamona Schulz, Matthias Dobbelstein, Ute M Moll
Journal of Molecular Cell Biology|December 9, 2016
Mdm2 as a chromatin modifierMagdalena Wienken, Ute M Moll, Matthias Dobbelstein
Pageof 10